Previous 10 | Next 10 |
Cortexyme ( CRTX -1.7% ) commences patient screening in Europe for its Phase 2/3 GAIN study evaluating lead candidate COR388 for the potential treatment of mild-to-moderate Alzheimer's disease. More news on: Cortexyme, Inc., Healthcare stocks news, Read more ...
- International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer’s disease - GAIN Trial opened for U.S. enrollment in Q2 2019 and is expected to include approximately 90 sites globally ...
Bellus Health ( BLUSF ) could have its shares soon trading on the NASDAQ exchange. This is a very favourable announcement. As a result, we believe that market liquidity will increase, which may push the share price of Bellus up. We are positive on the stock. Another stock catalyst, which may e...
-- Presentation to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, toda...
-- Rationale and design of the GAIN trial discussed in AAIC news briefing earlier this morning -- In Phase 1b testing, COR388 was associated with reductions in markers of inflammation and pathological ApoE fragmentation Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentati...
Noteworthy events during the week of July 14 - 20 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Cortexyme, Inc., Cytori Therapeutics, Inc., Healthcare stocks news, , Read more ...
- Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzhei...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board...
Gainers: MoneyGram International (NASDAQ: MGI ) +106% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +33% . G1 Therapeutics (NASDAQ: GTHX ) +26% . SunPower Corporation (NASDAQ: SPWR ) +24% . Sundance Energy Australia (NASDAQ: SNDE ) +20% . Cortexyme (NASDAQ: CRTX...
Company Overview Cortexyme ([[CRTX]]) is a clinical-stage biopharmaceutical company pioneering a new disease-modifying therapeutic approach to treating Alzheimer’s disease and other neuro-degenerative diseases. The company is targeting a specific pathogen found in the brain of Alzhe...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...